Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

4.130 -0.030 (-0.72%)
Streaming Delayed Price Updated: 10:00 AM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atea Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
5 Under 10: Low Share Price, Debt Free, Lots Of Cash ↗
A look at five low-priced stocks with lots of cash per share, and no or very low debt. Most of them have very low-cap stocks and should be considered very speculative. 
Via Talk Markets
News headline image
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Recap: Atea Pharmaceuticals Q4 Earnings ↗
 
Via Benzinga
News headline image
Atea Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
News headline image
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy ↗
Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for 
Via Benzinga
News headline image
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals's Earnings Outlook ↗
 
Via Benzinga
News headline image
Earnings Preview For Atea Pharmaceuticals ↗
 
Via Benzinga
News headline image
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
News headline image
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023 ↗
 
Via Benzinga
News headline image
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination
Combination Offers Opportunity to Improve Standard of Care with Potential for Short Duration, Protease Inhibitor-Free Treatment 
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy. 
Via Benzinga
News headline image
Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded mixed, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
Proposal Fundamentally Undervalues Atea; Not in the Best Interests of Atea or Its Shareholders 
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Biotech Bargain Hunt: Concentra Biosciences Eyes Atea's Promising COVID-19 Response ↗
Earlier today, Concentra Biosciences, an affiliate of Tang Capital, sent an acquisition proposal to Atea Pharmaceuticals Inc (NASDAQ: AVIR) at $5.75 per share, representing a 55% premium to Friday’s... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.